5/9/2006 – The Vaccine Company LP, which is focused on mutations of the myeloid cell line, said that it has raised the remaining $6 million of its $20 million Series C round.
5/9/2006 – The Vaccine Company LP, which is focused on mutations of the myeloid cell line, said that it has raised the remaining $6 million of its $20 million Series C round.
